医药板块震荡上行，恒生创新药ETF（159316）获资金持续布局

Core Viewpoint - The pharmaceutical sector is experiencing an upward trend, with various indices showing positive growth, driven by significant investments and government initiatives in drug innovation [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 0.6% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Biotechnology Theme Index both rose by 1.0% [1] - The CSI 300 Pharmaceutical and Health Index saw a rise of 1.1% [1] - The CSI Innovative Drug Industry Index increased by 1.4% [1] - The Hang Seng Innovative Drug ETF (159316) recorded over 50 million net subscriptions throughout the day [1] - As of last Friday, the Hang Seng Innovative Drug ETF (159316) attracted over 1 billion yuan in investments this month, ranking first in the Hong Kong innovative drug sector [1] Group 2: Government Initiatives - The "National Major Special Project for Innovative Drug Research and Development" has officially launched, aiming to establish a self-controlled national drug innovation system by 2035 [1] - The core objectives include breaking through key technologies, creating high-value clinical new drugs, and cultivating leading international pharmaceutical companies [1] - The initiative aims to position China among the top tier of global new drug research and development, establishing it as a center for new drug creation and a hub for the biopharmaceutical industry [1]